NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ: NAMS · HEALTHCARE · BIOTECHNOLOGY
$28.43
-1.01% today
Updated 2026-04-29
Market cap
$3.27B
P/E ratio
—
P/S ratio
145.26x
EPS (TTM)
$-1.72
Dividend yield
—
52W range
$17 – $42
Volume
0.9M
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-7.34M | $-29.51M | $10.66M | $-141.22M | $-158.56M | $-147.78M |
| Capital expenditures | $15989.00 | $24000.00 | $221000.00 | $24000.00 | $672000.00 | $246000.00 |
| Depreciation | — | — | — | — | — | — |
| Stock-based comp | $0.00 | $1.24M | $4.12M | $24.57M | $33.62M | $59.42M |
| Free cash flow | $-7.36M | $-29.54M | $10.44M | $-141.24M | $-159.24M | $-148.03M |
| Investing cash flow | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — |